{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-25-020257","form_type":"8-K","ticker":"FHTX","cik":"0001822462","company_name":"Foghorn Therapeutics Inc.","filed_at":"2025-04-28T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.932416+00:00","generated_at":"2026-05-23T05:10:14.727151+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Foghorn presents AACR preclinical data for FHD-909 and CBP/EP300 degraders; Phase 1 ongoing","bullets":["FHD-909 (SMARCA2 inhibitor) Phase 1 trial ongoing in SMARCA4-mutated solid tumors; NSCLC primary target.","Preclinical combo data: FHD-909 synergistic with pembrolizumab and KRAS inhibitors, supporting clinical exploration.","Selective CBP degrader synergistic with paclitaxel and abemaciclib in ER+ breast cancer models.","Selective EP300 degrader shows preclinical activity in DLBCL and multiple myeloma; no thrombocytopenia.","ARID1B degrader program update expected in 2H 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-25-020257","json":"https://secwatch.observer/filing/0001628280-25-020257.json","markdown":"https://secwatch.observer/filing/0001628280-25-020257.md","text":"https://secwatch.observer/filing/0001628280-25-020257.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1822462/000162828025020257/0001628280-25-020257-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1822462/000162828025020257/fhtx-20250428.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-23T05:10:14.727151+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}